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Abstract
Despite the well known importance of apolipoprotein (Apo) E in cholesterol efflux, the effect of ApoE on the expression of
ATP-binding cassette transporter A1 (ABCA1) has never been investigated. The objective of this study was to determine the
effect of ApoE on ApoB-carrying lipoprotein-induced expression of ABCA1, a protein that mediates cholesterol efflux. Our
data demonstrate that ApoB-carrying lipoproteins obtained from both wild-type and ApoE knockout mice induced ApoAI-
mediated cholesterol efflux in mouse macrophages, which was associated with an enhanced ABCA1 promoter activity, and
an increased ABCA1 mRNA and protein expression. In addition, these lipoproteins increased the level of phosphorylated
specificity protein 1 (Sp1) and the amount of Sp1 bound to the ABCA1 promoter. However, all these inductions were
significantly diminished in cells treated with ApoE-free lipoproteins, when compared to those treated with wild-type
lipoproteins. Enrichment with human ApoE3 reversed the reduced inducibility of ApoE-free lipoproteins. Moreover, we
observed that inhibition of Sp1 DNA-binding by mithramycin A diminished ABCA1 expression and ApoAI-mediated
cholesterol efflux induced by ApoB-carrying lipoproteins, and that mutation of the Sp1-binding motif in the ABCA1
promoter region diminished ApoB-carrying lipoprotein-induced ABCA1 promoter activity. Collectively, these data suggest
that ApoE associated with ApoB-carrying lipoproteins has an upregulatory role on ABCA1 expression, and that induction of
Sp1 phosphorylation is a mechanism by which ApoE upregulates ABCA1 expression.
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Introduction
Apolipoprotein (Apo) E is a major component of ApoB-carrying
lipoproteins chylomicron remnants and very-low density lipopro-
tein (VLDL). It was initially recognized for its receptor binding
function. Under physiological conditions, ApoE, by binding to cell
surface low-density lipoprotein receptor (LDLR) or LDLR-related
protein (LRP), initiates receptor-mediated endocytosis [1]. Further
studies reveal that ApoE has, among other functions, a role in
cholesterol efflux. Two mechanisms currently have been suggested
for ApoE-mediated cholesterol efflux. One of them involves
lipoprotein-associated ApoE [2,3]. Following receptor-mediated
endocytosis, ApoB-carrying lipoproteins disintegrate in the early
sorting endosomes. The lipid core and ApoB are directed into
lysosomal compartments, while ApoE and receptors are recycled
back to the plasma membrane, followed by ApoE resecretion [4].
ApoE recycling is accompanied with cholesterol efflux [2].
Impaired ApoE recycling has been shown to result in intracellular
cholesterol accumulation [3]. Another mechanism for ApoE-
mediated cholesterol efflux involves lipid-poor ApoE [5,6].
Increasing evidence indicates that many extrahepatic cells,
including macrophages, secret ApoE, which promotes macro-
phage cholesterol efflux by autocrine or paracrine. In this process,
lipid-poor ApoE accepts cholesterol released from macrophages
[5,6], resulting in assembly of nascent high-density lipoproteins
(HDL) [7,8].
Despite much progress in research of ApoE-mediated choles-
terol efflux, very little is known about the effect of ApoE on the
expression of cholesterol transporters. ATP-binding cassette
transporter A1 (ABCA1) is one of the plasma membrane proteins
that export excess cholesterol [9]. Loading cells with cholesterol or
oxysterol, or incubation with native or oxidized LDL has been
shown to induce ABCA1 expression [10–14]. It has been
suggested that increase in cellular cholesterol activates nuclear
transcription factor liver X receptor (LXR), which in turn induces
ABCA1 expression [15]. Two isoforms of LXR have been
identified in mammalian cells. LXRa is primarily expressed in
liver, kidney, macrophages and intestine, whereas LXRb is
ubiquitously expressed [16]. Oxysterols have been shown to
function as ligands that bind and activate LXR [11]. The
oxysterol-activated LXRs form heterodimers with retinoid X
receptor (RXR) and bind to the ABCA1 promoter, inducing
transcription [11,15]. A recent study showed that treatment of cells
with oxysterols induced physical interaction of specificity protein 1
(Sp1) with the LXR and RXR heterodimer in the ABCA1
promoter [17]. Inhibition of Sp1 DNA-binding attenuated
oxysterol-induced ABCA1 expression [17]. These observations
suggest that oxysterol-induced ABCA1 expression is modulated by
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regulation of ABCA1 expression.
The present report examined the effect of ApoE on ApoB-
carrying lipoprotein-induced ABCA1 expression in macrophages.
Our data demonstrate that ApoB-carrying lipoproteins from both
wild-type and ApoE knockout mice induced ABCA1 expression
and increased ABCA1 promoter activity, which was associated
with an enhanced Sp1 phosphorylation and increased Sp1 binding
to the ABCA1 promoter. The increased magnitude was signifi-
cantly less in macrophages treated with ApoE-free lipoproteins
than in cells treated with wild-type lipoproteins. ApoE enrichment
reversed the inhibitory effects of the ApoE-free lipoproteins. These
observations inform a novel function for ApoE, i.e., ApoE
associated with ApoB-carrying lipoprotein upregulates ABCA1
expression.
Methods
Animals
Wild-type C57BL/6 and ApoE knockout (ApoE
2/2) mice were
obtained from the Jackson laboratory (Bar Harbor, ME). The
ApoE
2/2 mice were generated by Piedrahita et al. [18] and were
backcrossed to C57BL/6 for over 10 generations. All mice at 3–4
months of age were fed a high-fat diet containing 15% fat and
1.25% cholesterol by weight (Harlan Teklad, Madison, WI) for 4
days. Blood (0.5–1 ml) was collected from the posterior vena cava
after mice were anesthetized with 0.03 ml of cocktail containing
80 mg/ml ketamine hydrochloride and 12 mg/ml xylazine
hydrochloride. To minimize oxidation, collected blood was
immediately mixed with 50 mM butylated hydroxytoluene and
2 mM EDTA and cooled on ice. All procedures for handling
animals were conducted following protocols approved by the
Institutional Animal Care and Use Committee at Meharry
Medical College (Protocol Number: 080530ZG124).
Lipoprotein isolation
Lipoproteins were isolated from the plasma of wild-type and
ApoE
2/2 mice, respectively. Mouse plasma mixed with 50 mMo f
butylated hydroxytoluene (BHT) was overlaid with a potassium
bromide (KBr) gradient solution (d: 1.063) and centrifuged at
120,000 rpm for 2 hrs with a Sorvall Discovery M150 ultracen-
trifuge (Kendro Laboratory Products, Asheville, NC). The upper
fraction containing ApoB-carrying lipoproteins was collected, and
dialyzed in phosphate buffered saline (PBS, pH 7.4) containing
10 mM EDTA at 4uC for 48 hrs, and filtered through a 0.45-mm
filter [19].
ApoE enrichment
The ApoE-free, ApoB-carrying (E
2/B) lipoproteins were
enriched with human ApoE3 as described by Clavey et al. [20].
The ApoE/cholesterol ratio in the ApoB-carrying lipoproteins
obtained from wild-type mice [21] and normolipidemic subjects
[22,23] is about 1–3:100 (10–30 mg ApoE : 1 mg cholesterol). In
this study, E
2/B lipoproteins were incubated with human ApoE3
(Sigma-Aldrich, St. Louis, MO) at a ratio of 10 mg ApoE : 1 mg
cholesterol at 37uC for 1 hr. The ApoE3-enriched, ApoB-carrying
(E3/B) lipoproteins were re-isolated by KBr gradient ultracentri-
fugation as described above to remove free ApoE.
Cholesterol efflux assay
Raw 264.7 cells (ATCC, Manassas, VA) grown in 24-well plates
were incubated with 5 mCi/ml of [1,2-
3H(N)]-cholesterol (Perkin
Elmer, Waltham, MA) in the presence or absence of 20 mg/ml of
E
+/B, E
2/B or E3/B lipoproteins for 24 hrs. After washed with
PBS, cells were further incubated with 20 mg/ml of human ApoAI
(Sigma-Aldrich) or culture medium. After a 2-hr incubation, the
culture medium was collected. Cells were lysed with 0.5 M
NaOH. The lysate and medium were mixed with scintillation fluid
for radioactivity assay using a Tri-Carb 2300TR Liquid
Scintillation Analyzer (Perkin Elmer). Cholesterol efflux was
expressed as the percentage of radioactivity in medium to total
radioactivity (cells plus medium) [9]. ApoAI-mediated cholesterol
efflux was calculated as the difference between the values obtained
in the presence or absence of ApoAI in the medium.
Quantitative real-time RT-PCR analysis
Raw2 64.7 cells grown in six-well plates were treated with
20 mg/ml of E
+/B, E
2/B or E3/B lipoproteins or culture medium
alone as a control for 4 hrs. Total RNA was extracted using a
RNeasy Mini kit (Qiagen, Valencia, CA), and subjected to reverse
transcription using PolyT and Superscript III First-Strand
(Invitrogen, Carlsbad, CA). The resulting cDNAs were subjected
to quantitative real-time PCR with an iCycler system (Bio-Bad,
Hercules, CA) using primers synthesized by Qiagen (Valencia,
CA) for amplification of ABCA1 and 3-phosphate dehydrogenase
(GAPDH) [24]. The expression levels of the ABCA1 mRNAs were
normalized to GAPDH mRNA.
Western blot analysis
Raw 264.7 cells grown in 6-well plates were treated with 20 mg/
ml of E
+/B, E
2/B or E3/B lipoproteins or culture medium alone
for 4 hrs. Cells were lysed with M-PER reagent supplemented
with protease inhibitor and a phosphatase cocktail [1 mM
Na3VO4, 1 mM dithiothreitol (DTT), and 1 mM phenylmethyl-
sulfonyl fluoride (PMSF)]. Protein concentrations in the lysates
were determined using a BCA protein assay kit. Samples
containing 40 mg of protein were subjected to on 6% (for
separation of phosphorylated and non-phosphorylated Sp1) or
10% (for separation of other proteins) sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Proteins were then transferred
to polyvinylidene fluoride membranes. Antibodies against Sp1,
ABCA1 and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA),
followed by detection with horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology), were used as
described previously [25]. Immunoreactive bands were visualized
using ECL-plus chemiluminescence reagent (GE Healthcare
Healthcare–Amersham, Piscataway, NJ) and analyzed with a
GS-700 Imaging Densitometer (Bio-Rad).
Chromatin immunoprecipitation (ChIP) assay
Raw 264.7 cells were plated in 100-mm tissue culture dishes and
treated with 20 mg/ml of E
+/B, E
2/B or E3/B lipoproteins or
culture medium alone for 4 hrs. The amount of Sp1 bound to the
ABCA1 promoter was determined by ChIP analysis as described
previously [24]. Briefly, macrophages were cross-linked with 1%
formaldehyde, and lysed in cell lysis buffer (5 mM PIPES, 85 mM
KCl, 0.5% Nonidet P-40, 1 mM PMSF, and protease inhibitor
cocktail, pH 8.0). Nuclei were isolated and homogenized in
nuclear lysis buffer (50 mM Tris–HCl, 1% SDS, 10 mM EDTA,
and protease inhibitor cocktail, pH 8.1), and then sonicated until
crosslinked chromatin was sheared to an average length of
0.3,1.0 kb. A 5 ml aliquot of supernatant was used as an input
control. The remaining lysate was diluted 10-fold with ChIP
dilution buffer (16.7 mM Tris–HCl, 167 mM NaCl, 0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, and protease inhibitor
cocktail, pH 8.1), and precleaned with salmon sperm DNA
(Invitrogen, Carlsbad, CA) and protein A-agarose (Santa Cruz
Biotechnology). The precleaned sample was incubated with Sp1
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Bound protein-DNA complexes were eluted with a solution
containing 0.1 M NaHCO3 and 1% SDS. Following reversion of
the protein-DNA crosslinks, DNA fragments in the eluate and
input controls were purified using the QIAquick PCR purification
kit (Qiagen), and then subjected to quantitative real-time PCR
using an iCycler system (Bio-Rad). The PCR primers used were:
forward 59-dTTCCCGTTTCCCGAAGGCTA-39 and reverse
59-dAACGCTGTTCTCTCCCTCTT-39. A 220-bp DNA frag-
ment containing the Sp1-binding site sequence of the ABCA1
promoter region was amplified. The amount of DNA-bound Sp1
was expressed as a ratio of the PCR product amplified from the
anti-Sp1 immunoprecipitants versus the input controls.
Luciferase and b-galactosidase assays
For functional analysis of the ABCA1 promoter, two 59-deletion
and one mutant ABCA1 promoter fragments were generated by
PCR using UltraPfu DNA Polymerase. For generation of the
deletion fragments, wild-type C57BL/6J mouse genomic DNA
was used as a template. The PCR reverse primer for these
fragments starts at nucleotide 205 downstream from the
transcription start site (TSS) of the ABCA1 gene. The forward
primers start at nucleotides 21094 or 2125 upstream from the
TSS of the ABCA1 gene for generation of a 1299-bp and a 330-bp
PCR fragment, respectively. The shorter PCR fragment, referred
to as ABC-125, was used as a template to generate a mutant
ABCA1 promoter fragment, in which the Sp1-binding site was
mutated. The PCR products were cloned into the KpnI-XhoI sites
of the pGL2 luciferase vector (Promega, Madison, WI). The
recombinant plasmid construct (or empty pGL-2 vector) and a b-
galactosidase expression plasmid (pCMV-SPORT-bgal, Promega)
were co-transfected into RAW264.7 cells using a Nucleofector II
as described previously [26]. The transfected cells were treated
with 20 mg/ml of E
+/B, E
2/B or E3/B lipoproteins or culture
medium alone for 4 hrs, and lysed with 100 ml of lysis buffer
provided by the luciferase assay kit or the galactosidase assay kit
(Galacto-Star
TM ß-Galactosidase Reporter Gene Assay System). A
10 ml aliquot of lysate was incubated in a 96-well plate at room
temperature for 2 min with 100 ml of luciferase assay reagent
(Promega) or for 60 min with 100 ml of galactosidase assay
reagent. Luminescence was measured using the BL10000
LumiCount (Packard BioScience, Meriden, CT). Luciferase
activity was expressed as the luminosity ratio of the luciferase
assay to the b-galactosidase assay [25].
Statistical analysis
Data were reported as mean 6 standard error of the mean.
Differences among cells treated with E
+/B, E
2/B, E3/B
lipoproteins or culture medium alone were analyzed by one-way
analysis of variance (ANOVA) and the Student’s unpaired t-test,
unless otherwise indicated. Statistical significance was considered
when P was less than 0.05. Statistix software (Statistix, Tallahassee,
FL) was used for statistical analysis. The number of experiments
performed is indicated in figure legends.
Results
The effect of ApoE on ApoB-carrying lipoprotein-induced
ABCA1 expression and cholesterol efflux
In this study, we first examined the effect of ApoB-carrying
lipoproteins on the expression of macrophage ABCA1, a plasma
membrane protein that transports cholesterol from cell membrane
to lipid-free ApoAI [27]. As shown in Fig. 1A–1B, the basal
ABCA1 protein level was relatively low. Treatment of macro-
phages with 20 mg/ml of E
+/B lipoproteins for 4 hrs elevated the
ABCA1 protein level by more than 3.2 fold (Fig. 1A–1B), which
was associated with a 3.7-fold increase in ABCA1 mRNA level
(Fig. 1C). In contrast, the same dose of E
2/B lipoproteins resulted
in only approximately 2-fold increase in ABCA1 mRNA and
protein. Enrichment with ApoE increased the ability of E
2/B
lipoproteins to induce ABCA1 expression. The level of ABCA1
mRNA and protein induced by E3/B lipoproteins was comparable
to that induced by E
+/B lipoproteins (Fig. 1A–1C). These
observations suggest that ApoE is indispensible for a full induction
of ABCA1 expression by ApoB-carrying lipoproteins, i.e., ApoE
has an upregulatory role in ApoB-carrying lipoprotein-induced
ABCA1 expression.
Having demonstrated the difference of ABCA1 expression
induced by ApoB lipoproteins in the presence or absence of ApoE,
we then studied the effect of these lipoproteins on ApoAI-induced
cholesterol efflux. Data in Fig. 1D show that treatment of
macrophages with either E
+/B or E
2/B lipoproteins enhanced
ApoAI-mediated cholesterol efflux. However, the enhancement
was significantly less in cells treated with E
2/B lipoproteins than
in those treated with E
+/B lipoproteins (2.8261.13% versus
1.1160.11%). The data in Fig. 1D also show that E3/B
lipoproteins induced similar amount of cholesterol efflux as E
+/
B lipoproteins. These findings imply that induction of ABCA1
expression might be one of the mechanisms by which ApoE
promotes cholesterol efflux.
The effect of ApoE on ApoB-carrying lipoprotein-induced
ABCA1 promoter activity
In this study, we initially examined the effect of E
+/B
lipoproteins on ABCA1 promoter activity by transfection of
macrophages with two ABCA1 promoter-luciferase reporter
chimeric constructs. One contains 1094 bp, and the other contains
125 bp of the ABCA1 promoter. We observed that the basal and
lipoprotein-induced promoter activities in these two fragments
were comparable (data not shown). We then compared the effect
of E
+/B, E
2/B and E3/B lipoproteins on ABCA1 promoter
activity using the promoter-luciferase reporter construct contain-
ing 125 bp of the ABCA1 promoter (ABC-125). The data in Fig. 2
show that treatment of macrophages with E
+/B, E
2/B or E3/B
lipoproteins induced about 2.4-, 1.5- and 2.2-fold elevation in
luciferase activity, respectively. The E
2/B lipoprotein-induced
luciferase activity was significantly lower than that induced by E
+/
B or E3/B lipoproteins. These data suggest that increasing
ABCA1 promoter activity is a mechanism by which ApoB-
carrying lipoproteins induce ABCA1 expression, and that ApoE
enhances the regulatory role of ApoB-carrying lipoproteins on
ABCA1 promoter activity.
It has been demonstrated Sp1 is a transcription factor that
controls ABCA1 expression [15,17]. Computer analysis of the
ABCA1 promoter shows a Sp1-binding site located 99 nucleotides
upstream of the TSS. As the data in Fig. 2 show, mutation of this
Sp1-binding motif significantly reduced the basal and lipoprotein-
induced expression of the reporter gene. Specifically, the basal
luciferase activity was about 40% lower in macrophages
transfected with the Sp1 motif-mutated ABCA1 promoter than
in those transfected with the wild-type ABCA1 promoter
counterpart (Fig. 2). Treatment with E
+/B or E3/B lipoproteins
induced only about 1.5-fold elevation in luciferase activity in
macrophages transfected with the mutated ABCA1 promoter,
while E
2/B lipoproteins did not induce any luciferase activity in
these cells. These inductions were significantly less than lipopro-
tein-induced luciferase activities in cells transfected with the wild-
type ABCA1 promoter. Taken together, the Sp1binding motif is
ApoE Regulates ABCA1 Expression
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activities in the presence or absence of ApoE.
The effect of ApoE on ApoB-carrying lipoprotein-induced
Sp1 binding to the ABCA1 promoter
To confirm the regulatory role of Sp1 in lipoprotein-induced
ABCA1 promoter activity, we determined the amount of Sp1
bound to the ABCA1 promoter in macrophages treated with E
+/
B, E
2/B and E3/B lipoproteins. As the data in Fig. 3 show, the
ability of ApoB-carrying lipoproteins to induce Sp1 binding to the
ABCA1 promoter region varied in the presence or absence of
ApoE. Specifically, the amount of Sp1 proteins bound to the
ABCA1 promoter was increased about 2.5 fold in macrophages
treated with E
+/B and E3/B lipoproteins, whereas the DNA-
bound Sp1 was increased only about 1.4-fold in cells treated with
E
2/B lipoproteins (Fig. 3). These results suggest that ApoE
enhances the capability of ApoB-carrying lipoproteins to induce
Sp1 binding to the ABCA1 promoter region.
The effect of ApoE on ApoB-carrying lipoprotein-induced
Sp1 expression and phosphorylation
To uncover the mechanism underlying the induction of Sp1
binding to the ABCA1 promoter by ApoB-carrying lipoproteins,
we examined the total and phosphorylated Sp1 protein levels. As
the typical western blot images in Fig. 4A illustrate, two Sp1
immunoreactive bands were detectable, indicating covalent
modifications in Sp1 proteins. While ApoB-carrying lipoprotein
treatment did not significantly alter the total Sp1 protein level, a
band shift was visualized in cells treated with lipoproteins (Fig. 4A).
Specifically, ApoB-carrying lipoproteins induced part of Sp1
proteins shifting to the top band. To determine whether the slow
migrating forms of Sp1 were generated by phosphorylation, we
incubated an aliquot of the cell lysate with l-phosphatase before
western blot analysis. As shown in Fig. 4A, l-phosphatase
abolished the slowly migrating form of Sp1 induced by ApoB-
carrying lipoproteins. These observations indicate that the
lipoprotein-induced shift of the Sp1 inmmunoreactive band is
due to Sp1 phosphorylation. The data in Fig. 4B show that the
level of Sp1 phosphorylation induced by E
2/B lipoproteins was
significantly reduced as compared to that induced byE
+/B and
E3/B lipoproteins. Increase in phosphorylation has been suggested
to enhance the activity of Sp1 to bind its cognate DNA sequences
[28]. Taken together, our data suggest that induction of Sp1
phosphorylation might be a mechanism by which ApoB-carrying
lipoproteins induce Sp1 binding to the ABCA1 promoter, and that
ApoE enhances the ability of ApoB-carrying lipoproteins to induce
Sp1 phosphorylation.
Mithramycin A inhibits ApoB-carrying lipoprotein-
induced ABCA1 expression and cholesterol efflux
To address whether Sp1 binding to ABCA1 promoter is
necessary for ApoB-carrying lipoprotein-induced expression of
ABCA1, we studied the effect of mithramycin A on ABCA1
expression. Mithramycin A is a chemotherapeutic drug that binds
to GC-rich DNA sequences thereby blocking the binding of Sp1 to
GC-specific regions of DNA [29]. A wide range of concentrations
of mithramycin A (10 nM–1 mM) have been used to inhibit the
transcriptional factor activity of Sp1 in various types of cells,
including human bronchial epithelial cells, multiple myeloma cells
[29,30], and mouse endothelial cells [25]. As the data Fig. 5A–5C
show, addition of 100 nM mithramycin A significantly diminished
Figure 1. The effect of ApoE on lipoprotein-induced ABCA1 expression and cholesterol efflux. For study the effect of ApoB-carrying
lipoproteins on ABCA1 expression, mouse macrophages were incubated with 20 mg/ml of wild-type (E
+/B), ApoE-free (EI ˆ/B) or ApoE3-enriched (E3/B)
lipoproteins, or culture medium alone. Panel A and B: The level of ABCA1 protein was determined by western blot analysis and quantitated relative
to b-actin. Panel C: The level of ABCA1 mRNA was determined by quantitative real-time RT-PCR and normalized to GAPDH mRNA. Panel D: For
studying the effect of ApoE on lipoprotein-induced cholesterol efflux, mouse macrophages were incubated with [
3H]-cholesterol in the presence or
absence of 20 mg/ml of E
+/B, E
2/B or E3/B lipoproteins. ApoAI-mediated cholesterol efflux was measured as described under Materials and Methods.
Values represent the mean 6 SEM of five independent experiments. Differences among cells treated with E
+/B, E
2/B, E3/B lipoproteins or culture
medium alone were analyzed by one-way ANOVA followed by Tukey post-hoc tests (B and C) or Student t-test (D). * P,0.05 compared to control,
{P,0.05 compared to E
+/B or E3/B lipoprotein treatment.
doi:10.1371/journal.pone.0021453.g001
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+/B and E
2/
B lipoproteins. These data suggest that binding of Sp1 protein to
the ABCA1 promoter is indispensible to ABCA1 expression
induced by ApoB-carrying lipoproteins in the presence or absence
of ApoE. In addition, inhibition of ABCA1 expression by
mithramycin A was associated with a reduced cholesterol efflux
(Fig. 5D), suggesting that induction of ABCA1 expression is a
mechanism for ApoB-carrying lipoprotein-induced cholesterol
efflux.
Discussion
Using ApoB-carrying lipoproteins obtained from ApoE knock-
out mice, this report demonstrates that lipoprotein-associated
ApoE has an upregulatory role on ABCA1 expression. In the
absence of ApoE, ApoB-carrying lipoproteins manifested reduced
ability to increase ABCA1 mRNA and protein in macrophages,
when compared to wild-type lipoproteins. Enrichment of ApoE-
free lipoproteins with ApoE3, the so-called normal isoform of
human ApoE, increased ABCA1 expression to the level similar to
that induced by wild-type lipoproteins. In agreement with the
ABCA1 expression level, the ApoAI-mediated cholesterol efflux
was significantly lower in macrophages treated with ApoE-free
lipoproteins than in those treated with ApoE-containing lipopro-
teins. It has been well-established that lipid-free ApoAI serves as a
cholesterol acceptor for ABCA1-mediatd cholesterol efflux [27].
Taken together, upregulation of ABCA1 expression may be one of
the mechanisms by which ApoE increases macrophage cholesterol
efflux. ApoE has been shown to regulate cholesterol efflux by its
recycling [2] and by functioning as a cholesterol acceptor [5,6].
Emerging evidence indicates that ABCA1 expression is tightly
regulated at the transcription level by cellular cholesterol content
[31]. Cholesterol-induced ABCA1 expression is attributed to
nuclear transcription factor LXR [10,31]. Paradoxically, a
previous work from our laboratory showed that the cholesterol
content was significantly higher in macrophages treated with
ApoB-carrying lipoproteins obtained from ApoE knockout mice
than in those treated with lipoproteins obtained from wild-type
mice [19]. In addition, the level of oxidized lipids was significantly
higher in ApoE-free lipoproteins than in wild-type lipoproteins
[19]. Although these data do not exclude the participation of
cholesterol-activated LXR in ApoB-carrying lipoprotein-induced
ABCA1 expression, they do suggest that mechanisms other than
increase in cell cholesterol level are responsible for the upregula-
tory role of ApoE on ABCA1 expression.
Data from this report clearly indicate that increase in the
transcriptional activity of Sp1 is a mechanism underlying the
upregulatory role of ApoB-carrying lipoproteins on ABCA1
expression. It is known that Sp1 regulates basal and inducible
transcription of many genes via binding to their promoter region
[32]. Mouse ABCA1 promoter contains one Sp1-binding site
located 99 nucleotides upstream the transcription start site. Our
data demonstrate that mutation of this DNA regulatory element
weakened the ABCA1 promoter activity induced by ApoB-
carrying lipoprotein. Inhibition of Sp1 DNA binding diminished
ABCA1 expression induced by ApoB-carrying lipoproteins. These
findings suggest that increasing Sp1 binding to its cognate DNA
sequence in the ABCA1 promoter region is a mechanism for
Figure 2. The effect of ApoE on lipoprotein-induced ABCA1
promoter activity. Pane A: Two constructs containing wild-type and
Sp1-binding site-mutated (Mut-Sp1) ABCA1 promoter region were
subcloned into a luciferase (Luc) reporter plasmid (pGL-2). The mutated
sequences in the Mut-Sp1 construct are shown in the schematic
diagram. Panel B: Mouse macrophages were transfected with a b-
galactosidase expression plasmid and the ABCA1 promoter-reporter
constructs or the empty pGL-2 vector. The transfected macrophages
were treated with 20 mg/ml of wild-type (E
+/B), ApoE-free (EI ˆ/B) or
ApoE3-enriched (E3/B) lipoproteins, or culture medium alone (control)
for 4 hrs. Luciferase activity was normalized to the b-galactosidase
activity and expressed relative to that of pGL2 basic vector. Values
represent the mean 6 SEM of five independent experiments. * P,0.05
compared to cells transfected with the same plasmid and without
lipoprotein treatment (control),
{P,0.05 compared to cells transfected
with the same plasmid and treated with E
+/B or E3/B lipoproteins, and
#P,0.05 compared to cells transfected with wild-type ABCA1 promoter
and treated with the same lipoproteins.
doi:10.1371/journal.pone.0021453.g002
Figure 3. The effect of ApoE on lipoprotein-induced Sp1 DNA-
binding activity. Mouse macrophages were treated with 20 mg/ml of
wild-type (E
+/B), ApoE-free (EI ˆ/B) or ApoE3-enriched (E3/B) lipoproteins,
or culture medium alone (control) for 4 hrs. The amount of Sp1 bound
to the ABCA1 promoter region was determined by ChIP analysis, and
expressed as the ratio of input controls. Values represent the mean 6
SEM of 5 separate experiments. * P,0.05 compared to control,
{P,0.05
compared to E
+/B or E3/B lipoprotein treatment.
doi:10.1371/journal.pone.0021453.g003
ApoE Regulates ABCA1 Expression
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treatment of macrophages with ApoB-carrying lipoproteins
increased Sp1 binding to the ABCA1 promoter region. Our data
also demonstrate that ApoB-carrying lipoproteins devoid of ApoE
displayed reduced ability to induce Sp1-ABCA1 promoter binding
and reduced ABCA1 promoter activity, when compared to ApoE-
containing lipoproteins. It appears that ApoE is indispensible for
efficient induction of Sp1 binding to the ABCA1 promoter by
ApoB-carrying lipoproteins.
Modification through phosphorylation has been suggested to
increase the DNA-binding activity of Sp1 [28]. Our data
demonstrate that ApoB-carrying lipoproteins induced Sp1 phos-
phorylation in mouse macrophages. Deficiency of ApoE diminished
the inducibility of ApoB-carrying lipoproteins on Sp1 phosphory-
lation, which is consistent with the reduced ABCA1 promoter
activity and ABCA1 expression induced by ApoE-free lipoproteins.
These findings suggest a role of ApoE in activation of protein
kinase(s) for Sp1 phosphorylation. Several kinases, including DNA-
dependent protein kinase, protein kinase C-f (PKC- f), phospha-
tidylinositol 3-kinase (PI3K), casein kinase II, extracellular signal-
regulated kinase(ERK),andcyclin-dependent kinase2 (Cdk2),have
been shown to mediate Sp1 phosphorylation [17]. Although the
kinase(s) responsible for ApoE-induced Sp1 phosphorylation have
not been defined, available evidence supports the view that ApoE is
able to induce signaling transduction. It is known that ApoB-
carrying lipoprotein-associated ApoE has high affinity for several
members of the LDLR family, including LDLR, VLDL receptor
(VLDLR), LRP1, LRP2, and LRP8 (ApoE receptor 2) [33]. While
the role of the LDLR is limited to the regulation of cholesterol
homeostasis by receptor-mediated endocytosis of lipoprotein
particles, the other members of the gene family have additional
physiological functions as signal transducers [33]. Thus, binding
and internalization of ApoE-carrying lipoproteins might activate
various signaling pathways, some of which may activate the protein
kinase(s) that phosphorylate Sp1. For example, activation of
VLDLR and LRP8 has been shown to activate PI3K [34]. In
Figure 4. The effect of ApoE on lipoprotein-induced Sp1
phosphorylation. Mouse macrophages were treated with 20 mg/ml of
wild-type (E
+/B), ApoE-free (EI ˆ/B) or ApoE3-enriched (E3/B) lipoproteins,
or culture medium alone (control) for 4 hrs. The cell lysate were
incubated with or without l-phosphatase. Sp1 phosphorylation was
detected by Sp1 immunoblot band shift induced by lipoprotein and l-
phosphatase treatments. The level of phosphorylated Sp1 was
expressed as the percentage of the immunoreactive intensity of the
top band versus the total (top plus bottom bands). Values represent the
mean 6 SEM of 3 separate experiments. * P,0.05 compared to control,
{P,0.05 compared to E
+ or E3 lipoprotein treatment.
doi:10.1371/journal.pone.0021453.g004
Figure 5. The effect of mithramycin A on lipoprotein-induced ABCA1 expression and cholesterol efflux. For study ABCA1 expression,
mouse macrophages were treated with 20 mg/ml of wild-type (E
+/B), ApoE-free (EI ˆ/B) or ApoE3-enriched (E3/B) lipoproteins, or culture medium
(control) in the presence or absence of 100 nM mithramycin A (mmA) for 4 hrs. Panel A and B: The level of ABCA1 protein was determined by
western blot analysis and quantitated relative to b-actin. Panel C: The level of ABCA1 mRNA was determined by quantitative real-time RT-PCR and
normalized to GAPDH mRNA. Panel D: For studying cholesterol efflux, mouse macrophages were incubated with [
3H]-cholesterol in the presence or
absence of 20 mg/ml of E
+/B, E
2/B or E3/B lipoproteins for 24 hrs. ApoAI-mediated cholesterol efflux was measured in the presence or absence of
mmA. Values represent the mean 6 SEM of five independent experiments. * P,0.05 compared to control,
{P,0.05 compared to cells treated with E
+/
B lipoproteins and without mmA, and
#P,0.05 compared to cells treated with E
2/B lipoproteins and without mmA.
doi:10.1371/journal.pone.0021453.g005
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has a function to activate PKC- f [35].
It is of interest that ApoB-carrying lipoproteins in the absence of
ApoE can also induce Sp1 phosphorylation, despite smaller
magnitude than in the presence of ApoE. These findings suggest
that other component(s) in the ApoB-carrying lipoproteins besides
ApoE can activate signaling pathway(s) involving protein kinase(s)
for Sp1 phosphorylation. It has been suggested that macrophages
are able to take up ApoB-carrying lipoproteins via scavenger
receptor (SR)-mediated pathways in the absence of ApoE [36,37].
Some SRs, such as SR-A, CD36 and LOX-1, have been implicated
to initiate intracellular signaling cascades [38,39]. It is highly likely
that the ApoE-independentpathway(s) alsoactivateproteinkinase(s)
that phosphorylate Sp1, inducing ABCA1 expression.
In summary, data from this report demonstrate that ApoB-
carrying lipoproteins, in the presence or absence of ApoE, are able
to induce macrophage ABCA1 expression via activation of
transcription factor Sp1. The magnitude of induction is signifi-
cantly greater in the presence of ApoE. These findings imply that
there exist two distinct pathways for induction of Sp1 phosphor-
ylation by ApoB-carrying lipoproteins, one depends on ApoE, and
the other does not. Under physiological conditions, ApoB-carrying
lipoproteins are internalized via ApoE-mediated pathways. The
ApoE-dependent Sp1 phosphorylation and ABCA1 induction thus
could be physiologically important for efflux of excess cholesterol
derived from ApoB-carrying lipoproteins.
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